Novel Biomarkers in the Continuum of Breast Cancer
(Sprache: Englisch)
This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today's standard therapies, and markers...
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
109.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Novel Biomarkers in the Continuum of Breast Cancer “
Klappentext zu „Novel Biomarkers in the Continuum of Breast Cancer “
This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today's standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research.Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment(s) for individual patients.
Inhaltsverzeichnis zu „Novel Biomarkers in the Continuum of Breast Cancer “
1 Genomic Biomarkers for Cancer Risk.- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum.- 3 Incorporating Biomarkers in Studies of Chemoprevention.- 4 Breast Molecular Profiling and Radiotherapy Considerations.- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer.- 6 Biomarkers for predicting response to Anti-HER2 Agents.- 7 Intratumor Heterogeneity in Breast Cancer.- 8 Intratumor Heterogeneity in Breast Cancer.- 9 Pharmacogenetic Predictors of Response.- 10 Metabolomics in Breast Cancer: Current Status and Perspectives.- 11 Circulating Tumor Cells.- 12 Circulating Plasma Tumor DNA.Autoren-Porträt
Dr. Vered Stearns is the Co-Director of the Breast Cancer Program at the Sidney Kimmel Comprehensive Cancer Center, Professor of Oncology, and Breast Cancer Research Chair in Oncology and Johns Hopkins School of Medicine. Dr. Stearns is an expert in novel drug investigation-her focus is also on surrogate markers that may influence risk of breast cancer and the effectiveness of drugs. She has published over 150 scientific publications and has received over 5,368 citations in her career.
Bibliographische Angaben
- 2016, 1st ed. 2016, XIX, 279 Seiten, 4 farbige Abbildungen, Maße: 16 x 24,1 cm, Gebunden, Englisch
- Herausgegeben: Vered Stearns
- Verlag: Springer, Berlin
- ISBN-10: 3319229087
- ISBN-13: 9783319229089
- Erscheinungsdatum: 29.03.2016
Sprache:
Englisch
Kommentar zu "Novel Biomarkers in the Continuum of Breast Cancer"
Schreiben Sie einen Kommentar zu "Novel Biomarkers in the Continuum of Breast Cancer".
Kommentar verfassen